Elena Giudice

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 09, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: February 10, 2026

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Journal: Journal of the National Cancer Institute

Published: December 22, 2025

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Journal: Research square

Published: November 19, 2025

Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression.

Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression.

Journal: ESMO open

Published: November 14, 2025

Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.

Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.

Journal: Nature communications

Published: September 26, 2025

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.

Current landscape of T-cell engagers in early-phase clinical development in solid cancers.

Journal: Frontiers in immunology

Published: July 14, 2025

Advances in treatment strategies for low-grade serous ovarian cancer.

Advances in treatment strategies for low-grade serous ovarian cancer.

Journal: Cancer treatment reviews

Published: June 26, 2025

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

Journal: ESMO open

Published: April 30, 2025

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Journal: ESMO open

Published: April 29, 2025

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026